Ecnoglutide 10mg
A novel cAMP-biased, long-acting GLP-1 receptor agonist studied for glycemic management and weight reduction.
Mechanism
Ecnoglutide acts as a biased GLP-1 receptor agonist that selectively stimulates the cyclic AMP signaling cascade while showing negligible beta-arrestin recruitment or receptor internalization.
Dosing
Clinical protocols document an initial titration baseline of 0.6 mg administered once weekly.
Reconstitution
Reconstituting a 10 mg vial with 2.0 mL of bacteriostatic water yields an operational working solution of 5 mg/mL.
Storage
Store unreconstituted lyophilized vials in a cool, light-protected refrigerator, and maintain reconstituted solutions at 2–8 °C without freezing.
Mix & measure Ecnoglutide 10mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Ecnoglutide 10mg
Vial strength → BAC water → target dose
Total doses in vial: 16.7
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Diabetes Starting / Initial Step | 0.6 mg once weekly | 0.12 mL (12 units) |
| Diabetes Maintenance / Intermediate | 1.2 mg once weekly | 0.24 mL (24 units) |
| Weight Management Escalation | 1.8 mg once weekly | 0.36 mL (36 units) |
| Maximal Investigated Dose | 2.4 mg once weekly | 0.48 mL (48 units) |
Reconstitution Steps
- 1
Disinfect the rubber stoppers of the ecnoglutide vial and the bacteriostatic water container using sterile alcohol swabs and allow them to dry.
- 2
Draw exactly 2.0 mL of bacteriostatic water into a reconstitution syringe.
- 3
Insert the needle into the peptide vial angled against the glass wall, letting the diluent trickle down gently without directly blasting the lyophilized cake.
- 4
Allow the solution to rest momentarily, then smoothly roll the vial between your palms to achieve complete dissolution without shaking.
- 5
Confirm the reconstituted liquid is completely clear and particulate-free prior to placing it in refrigerated storage at 2–8 °C.
Supplies Needed
Peptide Vial
Provides 10 mg of purified, lyophilized ecnoglutide for study.
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous administration of research doses.
Bacteriostatic Water
Serves as the sterile, preserved diluent to reconstitute the peptide into solution.
Alcohol Swabs
Utilized to sanitize vial tops and equipment contact points prior to reconstitution.
Why researchers study it
Investigation of body mass reduction and adiposity control
Evaluation of glycemic parameters and type 2 diabetes management
Research into cAMP-biased receptor pharmacology versus conventional GLP-1 agonists
Comparative metabolic modeling relative to other incretin mimetics
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Ecnoglutide (XW003) is an engineered glucagon-like peptide-1 analog designed for extended metabolic activity. Developed to activate downstream metabolic pathways with a unique signaling profile, the peptide exhibits selective cellular cascades that separate target activation from typical receptor internalization pathways. Structural additions, including an amino acid substitution and fatty-acid lipid chain conjugation, provide robust non-covalent albumin binding to support sustained pharmacokinetic exposure. Preclinical and phase 3 clinical evaluations have investigated the molecule across both glycemic regulation in type 2 diabetes models and systemic weight reduction. Its clinical validation includes regulatory recognition in select jurisdictions such as China, though it remains unauthorized by Western regulatory authorities such as the FDA. Investigative research protocols emphasize weekly administration regimes designed to assess body mass attenuation and insulin-sensitizing actions.
References
- 1.Guo et al., Molecular Metabolism, 2023 — Discovery of ecnoglutide, a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
- 2.Zhu et al., Nature Communications, 2024 — Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
- 3.Ji et al., The Lancet Diabetes & Endocrinology, 2025 — Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: phase 3 trial
- 4.He et al., The Lancet Diabetes & Endocrinology, 2025 — Ecnoglutide versus dulaglutide in type 2 diabetes on metformin (EECOH-2): a 52-week phase 3 non-inferiority trial
- 5.Zhu et al., Nature Communications, 2026 — Ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a phase 3 trial
- 6.Kumar et al., Endocrinology, Diabetes & Metabolism, 2026 — Comparative efficacy and safety of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis
- 7.Chen et al., Frontiers in Pharmacology, 2026 — No dose adjustment required for warfarin or metformin when coadministered with ecnoglutide
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.